Review Article

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma

Table 2

Summary of novel immunotherapeutic strategies for melanoma patients.

TargetTherapeutic strategyReference

Topoisomerase ITopoisomerase I inhibitor + anti-PD-L1 or anti-PD1 mAbs[79]
Polypeptide gp75Anti gp75 mAb + anti-PD1 mAb[81]
Histone deacetylase (HDAC)Pan-HDAC inhibitors + anti-PD1 mAb[82]
FasFas/Fas-ligand blocking mAbs[83]
CD40Anti-CD40 mAb + CpG ODNs[84]
CTLA-4 and GD2Anti-CTL-A4 mAb + anti-GD2 mAb conjugated with IL-2[84]
Regulatory cellsFoxp3 DNA/recombinant protein vaccine[85]
GP33-41 antigenAdenoviral vector expressing GP33-41 tumor-associated antigen[86]
UnknownDocetaxel + adoptive T cell transfer + DC immunotherapy[93]
MART-1MART-1-specific CD8+ T cells[94]